Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279314 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT04279314 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 154 participants.
The verdict
NCT04279314, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome
Interventions
- DRUG Trofinetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2020-01-29 |
| Est. Completion | 2022-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04279314
The ClinicalTrials.gov registry entry for NCT04279314 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trofinetide is the first listed.
NCT04279314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04279314 about?
NCT04279314 is a clinical study titled "Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome". To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome
What is the current status of trial NCT04279314?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2020-01-29. Estimated completion is 2022-08-19.
What interventions are being tested in trial NCT04279314?
The interventions under investigation include: Trofinetide (DRUG).
Who is sponsoring clinical trial NCT04279314?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.